Institutions / Merck & Co., Inc.

Merck & Co., Inc.

CIK 310158 · Institution · as of Jun 30, 2026merck.com ↗
Portfolio value
$526.41M
Positions
13
As of
Jun 30, 2026

Portfolio trend

Portfolio value

$526.41M+90.5%
$526.41M$401.34M$276.28MQ4 '25Q2 '26

Positions

13+8.3%
131312Q4 '25Q2 '26

Top holdings

Jun 30, 2026
CompanyClassValueShares% of portfolio
Personalis, Inc.PSNLCommon Stock$188.20M14,044,94335.8%
Moderna, Inc.—$161.64M2,308,19030.7%
Kymera Therapeutics, Inc.—$88.54M772,16516.8%
Aktis Oncology, Inc.AKTSCommon Stock$30.71M952,8445.8%
Eikon Therapeutics, Inc.—$21.75M1,666,6664.1%
Entrada Therapeutics, Inc.TRDACommon Stock$12.80M1,739,7682.4%
Sutro Biopharma, Inc.—$9.04M272,3511.7%
Alector, Inc.—$7.13M3,545,7191.4%
Evaxion A/SEVAXADR$3.76M1,214,1260.7%
Viridian Therapeutics, Inc.—$1.72M93,4140.3%
Xilio Therapeutics, Inc.XLOCommon Stock$1.02M105,9820.2%
TuHURA Biosciences, Inc./NVHURACommon Stock$45.5K19,4450.0%
Neuphoria Therapeutics Inc.NEUPCommon Stock$43.8K10,0270.0%

Activity

Jun 30, 2026View full history →
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.
DateActionCompanyValueShares ΔPosition afterImpact
Q2 2026
as of
NewAKTS
Aktis Oncology, Inc.
Common Stock
$30.71M+953K
952,844
5.83% of portfolio
medium
Q2 2026
as of
NewEikon Therapeutics, Inc.$21.75M+1.7M
1,666,666
4.13% of portfolio
medium
Q2 2026
as of
Exit29384C908$-17.88M-1.7M
-100.00%
—
medium
Q2 2026
as of
NewTRDA
Entrada Therapeutics, Inc.
Common Stock
$12.80M+1.7M
1,739,768
2.43% of portfolio
medium
Q2 2026
as of
NewSutro Biopharma, Inc.$9.04M+272K
272,351
1.72% of portfolio
medium
Q2 2026
as of
Exit29970R204$-5.79M-1.2M
-100.00%
—
medium
Q2 2026
as of
NewEVAX
Evaxion A/S
ADR
$3.76M+1.2M
1,214,126
0.71% of portfolio
low
Q2 2026
as of
ExitSutro Biopharma, Inc.$-3.15M-272K
-100.00%
—
low
Q2 2026
as of
NewXLO
Xilio Therapeutics, Inc.
Common Stock
$1.02M+106K
105,982
0.19% of portfolio
low
Q2 2026
as of
Exit98422T100$-949.9K-1.5M
-100.00%
—
low